You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR GALLIUM GA-68 EDOTREOTIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for gallium ga-68 edotreotide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03001349 ↗ 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Terminated National Cancer Institute (NCI) Early Phase 1 2017-05-16 This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
NCT03001349 ↗ 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Terminated M.D. Anderson Cancer Center Early Phase 1 2017-05-16 This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
NCT06091748 ↗ Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors Not yet recruiting Jiangsu HengRui Medicine Co., Ltd. Phase 3 2023-11-01 This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for gallium ga-68 edotreotide

Condition Name

Condition Name for gallium ga-68 edotreotide
Intervention Trials
Advanced Gastroenteropancreatic Neuroendocrine Tumor 1
Meningioma 1
Metastatic Well Differentiated Neuroendocrine Neoplasm 1
Multiple Endocrine Neoplasia Type 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for gallium ga-68 edotreotide
Intervention Trials
Neuroendocrine Tumors 2
Neoplasms 1
Multiple Endocrine Neoplasia Type 1 1
Multiple Endocrine Neoplasia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for gallium ga-68 edotreotide

Trials by Country

Trials by Country for gallium ga-68 edotreotide
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for gallium ga-68 edotreotide
Location Trials
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for gallium ga-68 edotreotide

Clinical Trial Phase

Clinical Trial Phase for gallium ga-68 edotreotide
Clinical Trial Phase Trials
Phase 3 1
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for gallium ga-68 edotreotide
Clinical Trial Phase Trials
Not yet recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for gallium ga-68 edotreotide

Sponsor Name

Sponsor Name for gallium ga-68 edotreotide
Sponsor Trials
National Cancer Institute (NCI) 1
M.D. Anderson Cancer Center 1
Jiangsu HengRui Medicine Co., Ltd. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for gallium ga-68 edotreotide
Sponsor Trials
Industry 1
NIH 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.